Jade Biosciences Quarterly Balance Sheet
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jade Biosciences financial position
As of Jun 30, 2026, Jade Biosciences reported total assets of $472.1 million, up 110.8% from a year earlier against total liabilities of $32.2 million. Shareholders' equity stood at $439.9 million, or 93.2% of assets. The company held $107.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 14.93, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Jade Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 107.25M | 55.09M | 88.44M | 50.11M | 220.94M | 44.22M | 69.39M | 31.11M | 31.07M | 9.12M | 23.49M | 32.18M |
| Short-Term Investments | 353.95M | 256.21M | 247.72M | 148.80M | — | 31.99M | 0 | 57.62M | 73.13M | 90.21M | 98.95M | 103.02M |
| Total Current Assets | 471.25M | 318.52M | 348.82M | 201.36M | 222.98M | 77.37M | 69.65M | 90.61M | 110.76M | 103.24M | 124.23M | 137.60M |
| Property, Plant & Equipment | 144.00K | 157.00K | 170.00K | 176.00K | 147.00K | 2.00K | 0 | 14.00K | 232.00K | 260.00K | 288.00K | 316.00K |
| Total Assets | 472.11M | 319.43M | 349.78M | 202.45M | 223.97M | 77.53M | 72.80M | 90.96M | 111.69M | 106.82M | 127.42M | 140.88M |
| Accounts Payable | 6.58M | 3.98M | 2.15M | 1.35M | 7.59M | 69.00K | 1.29M | 908.00K | 4.18M | 3.31M | 2.40M | 3.50M |
| Total Current Liabilities | 31.57M | 22.29M | 16.54M | 22.36M | 21.62M | 2.42M | 12.00M | 10.31M | 17.02M | 15.52M | 17.64M | 14.72M |
| Total Liabilities | 32.20M | 22.97M | 17.26M | 23.10M | 22.41M | 2.49M | 119.60M | 10.47M | 17.30M | 15.92M | 17.96M | 15.15M |
| Shareholders' Equity | 439.92M | 296.46M | 332.52M | 179.35M | 201.56M | -83.51M | -46.80M | -16.86M | -589.00K | 90.90M | 109.46M | 125.72M |
| Retained Earnings | -270.52M | -214.76M | -174.39M | -142.46M | -117.28M | -235.57M | -46.98M | -227.62M | -211.38M | -186.61M | -163.42M | -143.01M |
| Net Cash (Debt) | 461.20M | 311.30M | 336.16M | 198.91M | 220.94M | 76.21M | 69.39M | 88.73M | 104.20M | 99.33M | 122.44M | 135.20M |
| Shares Outstanding | 63.56M | 49.35M | 49.32M | 32.63M | 32.63M | 28.99M | 3.67M | 28.87M | 28.85M | 27.90M | 27.76M | 27.65M |
This table shows 12 quarterly periods of Jade Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow JBIO's reporting calendar. What is a balance sheet?